Table 1.
Baseline clinical and procedural characteristics
| Total (n=181) | Low-MPV* (n=89) | High-MPV* (n=92) | P ** | |
|---|---|---|---|---|
| Age, years | 58.2±10.9 | 57.7±10.6 | 58.7±11.4 | 0.495 |
| Sex | 0.108 | |||
| Male | 124 (68.5) | 66 (74.2) | 58 (63.0) | |
| Female | 57 (31.5) | 23 (25.8) | 34 (37) | |
| Body mass index | 27.4±4.4 | 27.5±4.4 | 27.2±4.4 | 0.670 |
| MACE incidence | 29 (16) | 10 (11.2) | 19 (20.7) | 0.084 |
| Prior myocardial infarction | 71 (39.2) | 34 (38.2) | 37 (40.2) | 0.781 |
| Prior PCI | 33 (18.2) | 17 (19.1) | 16 (17.4) | 0.766 |
| Diabetes mellitus | 30 (16.6) | 13 (14.6) | 17 (18.5) | 0.484 |
| Dyslipidemia | 87 (48.1) | 46 (51.7) | 41 (44.6) | 0.338 |
| Hypertension | 89 (49.2) | 48 (53.9) | 41 (44.6) | 0.208 |
| Prior cerebrovascular events | 3 (1.66) | 0 (0) | 3 (3.3) | 0.086 |
| Smoking | 81 (44.8) | 35 (39.3) | 46 (50.0) | 0.149 |
| Familial history of CAD | 54 (29.8) | 21 (23.6) | 33 (35.9) | 0.071 |
| LVEF, % | 0.015 | |||
| ≥40% | 125 (69.1) | 69 (77.5) | 56 (60.9) | |
| <40% | 56 (30.1) | 20 (22.5) | 36 (39.1) | |
| Intervened vessel | ||||
| LAD | 101 (52.9) | 52 (51.5) | 49 (48.5) | 0.484 |
| RCA | 63 (31.6) | 28 (44.4) | 35 (55.6) | 0.353 |
| LCX | 35 (17.6) | 15 (42.9) | 20 (57.1) | 0.405 |
| Drug history | ||||
| β-blocker | 134 (74) | 68 (76.4) | 66 (71.7) | 0.474 |
| Statins | 103 (56.9) | 49 (55.1) | 54 (58.7) | 0.621 |
| Aspirin | 63 (34.8) | 32 (36.0) | 31 (33.7) | 0.094 |
| Dual antiplatelet | 72 (39.8) | 30 (33.7) | 42 (45.7) | 0.101 |
| Serum measurements | ||||
| Platelet count, 109/L | 209±56.9 | 225±56.4 | 194±53.1 | <0.001 |
| PDW, fL | 12.8±2.7 | 11.6±2.7 | 13.9±2.3 | <0.001 |
| P-LCR, % | 23.7±7.3 | 18.2±3.8 | 29.0±5.8 | <0.001 |
| Cholesterol, mg/dL | 157.5±34.2 | 160.6±34.3 | 154.4±34.0 | 0.218 |
| Triglyceride, mg/dL | 172.6±87.7 | 175.3±91.0 | 170.1±84.8 | 0.695 |
| LDL, mg/dL | 86.7±25.0 | 88.2±25.4 | 85.2±24.7 | 0.412 |
| HDL, mg/dL | 40.6±9.1 | 41.8±8.3 | 39.5±9.8 | 0.091 |
| Hematocrit, % | 39.3±5.6 | 38.8±5.8 | 39.7±5.4 | 0.299 |
| ALT, mg/dL | 31±36 | 28.9±21.9 | 33.2±45.9 | 0.297 |
| AST, mg/dL | 24.9±22.4 | 23.1±13.1 | 26.6±28.7 | 0.431 |
| Creatinine, mg/dL | 0.9±0.5 | 0.9±0.4 | 0.9±0.6 | 0.778 |
Values are presented as mean±SD and number (%)
*
MPV level was considered as low-MPV <9.6 fL and high-MPV ≥9.6 fL
**
Chi-square and t-test were used
ALT - alanine aminotransferase; AST - aspartate aminotransferase; CAD - coronary artery disease; HDL - high density lipoprotein; LAD - left anterior descending artery; LCX - left circumflex artery; LDL - low density lipoprotein; LVEF - left ventricular ejection fraction; MACE - major adverse cardiac event; MPV - mean platelet volume; PCI - percutaneous coronary intervention; PDW - platelet distribution width, P-LCR - platelet large-cell ratio, RCA - right coronary artery